Health Outcomes ResearchEffect of Bothersome Overactive Bladder Symptoms on Health-related Quality of Life, Anxiety, Depression, and Treatment Seeking in the United States: Results From EpiLUTS
Section snippets
Study Design and Participants
EpiLUTS is a population-based, cross-sectional Internet survey conducted in the United Kingdom, Sweden, and the United States to evaluate the prevalence, bother, and effect of OAB and other lower urinary tract symptoms (LUTS).10 Only the U.S. results are reported in the present study; the results on the burden of OAB symptoms in the United Kingdom and Sweden11 and across the total population12 have been previously published.
Participants were recruited from Internet-based panels developed from
Results
From approximately 1.5 million potential participants, 62 301 were randomly selected and sent electronic mail invitations. Responses were received from 36 821 participants, of whom 31 588 completed the survey. To address the overabundance of younger respondents in the eligible surveys relative to the target population, 20 000 surveys (9416 men and 10 584 women) were randomly selected for statistical matching to the 2005 American Community Survey demographics13 to ensure population
Comment
Patients with OAB must cope with symptoms of urgency, frequency, UUI, and nocturia on a daily and, perhaps, lifelong basis, given the chronic nature of OAB. A large proportion of patients with OAB are bothered by these symptoms. Numerous population studies have described the effect of OAB and UUI on bother and HRQL.20 Unlike many previous studies on the prevalence and effect of OAB, the present analysis differentiated between those with bothersome OAB symptoms and those with OAB symptoms that
Conclusions
Data from the EpiLUTS survey indicate that the burden of OAB symptoms on men and women in the United States is considerable. The strongest predictor of OAB-associated bother was urinary urgency. Although not all those with OAB were bothered by their symptoms, for those who are, the worsening of HRQL and increase in anxiety and depression can be significant.
References (23)
- et al.
National community prevalence of overactive bladder in the United States stratified by sex and age
Urology
(2011) - et al.
Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder
Eur Urol
(2009) - et al.
Bother related to bladder control and health care seeking behavior in adults in the United States
J Urol
(2009) - et al.
The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder
Eur Urol
(2006) - et al.
The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population-based FINNO study
Eur Urol
(2011) - et al.
Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder
Clin Ther
(2001) - et al.
The standardisation of terminology of lower urinary tract function: report from the standardisation Sub-Committee of the International Continence Society
Neurourol Urodyn
(2002) - et al.
An International Urogynecological Association (IUGA)/international Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction
Neurourol Urodyn
(2010) - et al.
Prevalence and burden of overactive bladder in the United States
World J Urol
(2003) - et al.
The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study
BJU Int
(2008)
It's just the worry about not being able to control it! A qualitative study of living with overactive bladder
Br J Health Psychol
Cited by (0)
Financial Disclosure: I. Milsom is a scientific consultant for Pfizer and United BioSource; an investigator for Pfizer and Astellas; a lecturer for Pfizer, Astellas, and Novartis; and receives grant support from Pfizer and Astellas. S. A. Kaplan is a consultant and member of the Speakers Bureau for Pfizer. K. S. Coyne and C. C. Sexton are employees of United BioSource Corporation, who were paid consultants to Pfizer in connection with the development of this report. Z. Kopp was an employee of Pfizer at the time this study was conducted.
Funding Support: This study was sponsored by Pfizer, Inc. Medical writing support was provided by Colin P. Mitchell, Ph.D., and Karen Zimmermann at Complete Healthcare Communications, Inc., and was funded by Pfizer, Inc.